Request Discount

Artemisinin Combination Therapy Market (Therapy Type - Artesunate-amodiaquine, Artemether-lumefantrine, Dihydroartemisinin-piperaquine, Artesunate-sulfadoxine-pyrimethamine, Pyronaridine-artesunate, and Artesunate-mefloquine; Distribution Channel - Hospitals, Clinics and Pharmacies, Retail and Drug Stores, and Others): Global Industry Analysis, Trends, Size, Share and Forecasts to 2027

  • Published : March, 2022

  • Rep Id : HC08758

  • Category : Healthcare & Medical Devices

  • Status : Published

A recent report published by Infinium Global Research on the artemisinin combination therapy market provides in-depth analysis of segments and sub-segments in the global as well as regional artemisinin combination therapy market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional artemisinin combination therapy market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of the global artemisinin combination therapy market. According to the report, the global artemisinin combination therapy market is projected to grow at a CAGR of 8% over the forecast period of 2021-2027.


Market Insight

The revenue generated by the market was approximately USD 512 million in 2021 and is expected to reach approximately USD 829 million in 2027. Artemisinin is a derivative of plant extracted from Artemisia annua, that has been shown to reduce the amount of plasmodium parasites in malaria patients' blood effectively and quickly. For uncomplicated falciparum malaria, artemisinin-based combination therapies (ACTs) are now widely regarded as the most effective treatment. They work quickly and consistently. Artemisinin Combination Therapy became the first line of treatment as sulfadoxine–pyrimethamine and chloroquine became ineffective and non-lethal as falciparum malaria bacteria developed a resistance towards these drugs. Even World Health Organization has classified Artemisinin Combination Therapy as the primary treatment of uncomplicated falciparum malaria. The Artemisinin Combination Therapy types are Artesunate-Amodiaquine, Artemether-Lumefantrine, Dihydroartemisinin-Piperaquine, Artesunate-Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate, Artesunate-Mefloquine and can be accessed through hospitals, clinics, pharmacies and other distribution channels.


According to WHO there were around 241 million cases of malaria around the world in 2020. In 2020, the number of deaths due to malaria were 627,000. Also, WHO mentioned that out of 241 million cases 95% of cases belonged to Africa and over 96% of malaria deaths. Artemisinin Combination Therapy provides a safe and effective way of curing malaria in these under-developing countries. Therefore, Prevalence of malaria in under-developing countries is propelling the growth of the market. The accessibility to Artemisinin Combination Therapy is also growing due to improvement in healthcare infrastructure in under-developing countries. International organizations such as WHO, World Bank and others are sending aids and funding healthcare infrastructure projects in under-developing countries which is expected to significantly increases the access of people to healthcare infrastructure such as hospitals and clinics. This factor is expected to aid the growth of the market. The Artemisinin Combination Therapy are costly which is expected to restrain the growth of the market. Nevertheless, new opportunities are expected to arise as the research and development for new combination therapies of Artemisinin is growing.


The Artemisinin Combination Therapy market is segmented region wise into North America, Europe, Asia-Pacific and Rest of the World. Asia-Pacific is expected to be the biggest market region wise. In 2020, Africa had over 96% of total malaria cases in the world according to World Health Organization. The widespread prevalence is the major factor responsible for the strong growth of the market in Africa. Other factors supporting the growth of the market are the growing income level of people and growing accessibility to Artemisinin Combination Therapy.


Segment Covered

The report on global artemisinin combination therapy market covers segments such as therapy type, and distribution channel. On the basis of therapy type, the sub-markets include artesunate-amodiaquine, artemether-lumefantrine, dihydroartemisinin-piperaquine, artesunate-sulfadoxine-pyrimethamine, pyronaridine-artesunate, and artesunate-mefloquine. On the basis of distribution channel, the sub-markets include hospitals, clinics and pharmacies, retail and drug stores, and others.


Companies Profiled:

The report provides profiles of the companies in the market such as Novartis AG, Cipla Ltd, Sanofi SA, Desano Holdings Ltd., KPC Pharmaceuticals Inc., Guilin Pharmaceuticals, Calyx Chemicals and Pharmaceuticals Ltd., DENK PHARMA GmbH & Co. KG, Mylan N.V., and Hovid Berhad .


Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of artemisinin combination therapy market. Moreover, the study highlights current market trends and provides forecast from 2021-2027. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.

Other Reports in This Category
24 hour delivery through email
9923950043 Monday to Frieday 9am-7pm
looking for discount